Search

Your search keyword '"Du, Yi-Chun"' showing total 237 results
Start Over Author "Du, Yi-Chun"
237 results on '"Du, Yi-Chun"'

24. Chaos Synchronization Detector Combining Radial Basis Network for Estimation of Lower Limb Peripheral Vascular Occlusive Disease

Author

Lin, Chia-Hung, Chen, Yung-Fu, Du, Yi-Chun, Wu, Jian-Xing, Chen, Tainsong, Hutchison, David, editor, Kanade, Takeo, editor, Kittler, Josef, editor, Kleinberg, Jon M., editor, Mattern, Friedemann, editor, Mitchell, John C., editor, Naor, Moni, editor, Nierstrasz, Oscar, editor, Pandu Rangan, C., editor, Steffen, Bernhard, editor, Sudan, Madhu, editor, Terzopoulos, Demetri, editor, Tygar, Doug, editor, Vardi, Moshe Y., editor, Weikum, Gerhard, editor, Zhang, David, editor, and Sonka, Milan, editor

Published
2010
Full Text
View/download PDF

26. Using Modified Contour Deformable Model to Quantitatively Estimate Ultrasound Parameters for Osteoporosis Assessment

Author

Chen, Yung-Fu, Du, Yi-Chun, Tsai, Yi-Ting, Chen, Tainsong, Hutchison, David, Series editor, Kanade, Takeo, Series editor, Kittler, Josef, Series editor, Kleinberg, Jon M., Series editor, Mattern, Friedemann, Series editor, Mitchell, John C., Series editor, Naor, Moni, Series editor, Nierstrasz, Oscar, Series editor, Pandu Rangan, C., Series editor, Steffen, Bernhard, Series editor, Sudan, Madhu, Series editor, Terzopoulos, Demetri, Series editor, Tygar, Doug, Series editor, Vardi, Moshe Y., Series editor, Weikum, Gerhard, Series editor, and Zhang, David, editor

Published
2007
Full Text
View/download PDF

29. Additional file 1 of Multifunctional nanocomposites DDMplusAF inhibit the proliferation and enhance the radiotherapy of breast cancer cells via modulating tumor-promoting factors and metabolic reprogramming

Author

Thabet, Noura M., Abdel-Rafei, Mohamed K., El-Sayyad, Gharieb S., Elkodous, Mohamed Abd, Shaaban, Adel, Du, Yi-Chun, Rashed, Laila Ahmed, and Askar, Mostafa A.

Subjects
skin and connective tissue diseases
Abstract

Additional file 1: Data S1. Stability of DDMPlusAF nanocomposites by DLS and zeta (ζ) potential analyses. Data S2. Cell survival and radio-sensitization of DDM, AF and DDMPlusAF via M-MTT assay at 24, 48 and 72h in comparison: a) MCF-7 and b) MDA cells. Data are mean ± SEM (n = 3), where control cells are set at 100%. Columns with letter a= significant from MCF-7 or MDA cells, b= significant from MCF-7+DDMPlusAF or MDA+DDMPlusAF, c = significant from MCF-7+DDMPlusAF+3Gy or MDA+DDMPlusAF+3Gy, and d = significant from MCF-7+DDMPlusAF+6Gy or MDA+DDMPlusAF+6Gy associated with * = significant from 24 h, # = significant from 48h and @ = significant from72h, in each histogram at P < 0.05. Data S3. Diagram of DDM (a) and AF (b) synthesis.

Published
2022
Full Text
View/download PDF

43. Multifunctional nanocomposites DDMplusAF inhibit the proliferation and enhance the radiotherapy of breast cancer cells via modulating tumor-promoting factors and metabolic reprogramming.

Author

Thabet, Noura M., Abdel-Rafei, Mohamed K., El-Sayyad, Gharieb S., Elkodous, Mohamed Abd, Shaaban, Adel, Du, Yi-Chun, Rashed, Laila Ahmed, and Askar, Mostafa A.

Subjects
CANCER cells, DOSE-response relationship (Radiation), BREAST cancer, CANCER radiotherapy, CANCER cell growth, CELL cycle
Abstract

Background: Tumor-promoting factors (TPF) and metabolic reprogramming are hallmarks of cancer cell growth. This study is designed to combine the newly synthesized two nanocomposites DDM (HA-FA-2DG@DCA@MgO) and AF (HA-FA-Amygdaline@Fe2O3) with fractionated doses of radiotherapy (6 Gy-FDR; fractionated dose radiotherapy) to improve the efficiency of chemo-radiotherapy against breast cancer cell lines (BCCs; MCF-7 and MDA-MB-231). The physicochemical properties of each nanocomposite were confirmed using energy dispersive XRD, FTIR, HR-TEM, and SEM. The stability of DDMPlusAF was also examined, as well as its release and selective cellular uptake in response to acidic pH. A multiple-MTT assay was performed to evaluate the radiosensitivity of BCCs to DDMPlusAF at 3 Gy (single dose radiotherapy; SDR) and 6 Gy-FDR after 24, 48, and 72 h. Finally, the anti-cancer activity of DDMPlusAF with 6 Gy-FDR was investigated via assessing the cell cycle distribution and cell apoptosis by flow cytometry, the biochemical mediators (HIF-1α, TNF-α, IL-10, P53, PPAR-α, and PRMT-1), along with glycolytic pathway (glucose, HK, PDH, lactate, and ATP) as well as the signaling effectors (protein expression of AKT, AMPK, SIRT-1, TGF-β, PGC-1α, and gene expression of ERR-α) were determined in this study. Results: The stability of DDMPlusAF was verified over 6 days without nanoparticle aggregation. DDMPlusAF release and selectivity data revealed that their release was amenable to the acidic pH of the cancer environment, and their selectivity was enhanced towards BCCs owing to CD44 and FR-α receptors-mediated uptake. After 24 h, DDMPlusAF boosted the BCC radiosensitivity to 6 Gy-FDR. Cell cycle arrest (G2/M and pre-G1), apoptosis induction, modulation of TPF mediators and signaling effectors, and suppression of aerobic glycolysis, all confirmed DDMPlusAF + 6 Gy's anti-cancer activity. Conclusions: It could be concluded that DDMPlusAF exerted a selective cancer radiosensitizing efficacy with targeted properties for TPF and metabolic reprogramming in BCCs therapy. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results